IPOs

Nasdaq celebrates epic biotech IPO success in 2018. But can the party on Wall Street rumba on?

On Thursday night Moderna {$MRNA} proved that a unicorn can still raise record sums with a biotech IPO on Nasdaq. And by the time the market closed Friday, the 20% drop in their share price also had more than a few people wondering if the party on Wall Street was finally winding down.

One way or the other, though, 2018 has provided a record bounty of IPO cash for biotech. Nasdaq crunched the numbers year-to-date, and concluded that Moderna — along with two other unicorn listings for Allogene and Rubius that attracted huge sums this year along with 66 much-smaller outfits — had raised $8.2 billion for the new class of public companies.

That sum even broke through the $6.5 billion in cash raised during the go-go days of 2014, when the long IPO draught triggered by the 2008 crisis finally ended in a deluge of 81 new listings. Back in 2014, though, a big group of 43% of those IPOs had to price below their range, with 57% in the range or higher. So far this year, that success rate is a far more bullish 83%.

Here are the figures:


In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)

← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 44,900+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 44,900+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Sr. Manager, Regulatory Affairs, CMC
CytomX Therapeutics San Francisco, CA
Marketing Associate - Demand Generation
Catalytic Data Science Charleston, SC
Associate Principal, Life Sciences Partnerships
Flatiron Health New York City or San Francisco

Visit Endpoints Careers ->